IPhone / Mobile Compatible

Viewport Meta

HSTS

nginx

DMARC

Microsoft Exchange Online

Office 365 Mail

Cloudflare CDN

jsDelivr

Co-Founder, Senior Vice President of Product Development

Erandi De Silva

Sales and Support

John Maslowski

Co-Founder and COO

M. Eicholtz

CEO/President/Co-Founder

Timothy Miller

Chief Financial Officer

Christina Perry

Senior Vice President of Regulatory Affairs

Christopher Shilling

Vice President of Process Development

Frank Agbogbo

Senior Vice President, Head of Business Development

Magdalena Tyrpien

Vice President of Quality Management

Meghan Leonard

Senior Vice President

Steven Goden

Fred Callori

Chris Garabedian

Matthew Hammond

Timothy J Miller

Co-Founder & President, Chief Executive Officer

Co-founder and Senior Vice President of Product Development

Chief Commercial Officer

Jaysson Eicholtz

Co-Founder and Chief Operating Officer

Great Lakes Companies With Less Than $50M in Revenue (Top 10K)

Biotechnology Acquired Companies With Less Than $10M in Revenue

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than 50 Employees (Top 10K)

Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.

It was founded in 2020 and headquartered in Grove City, Ohio.

Aisling Capital

Drive Capital

Series C - Forge Biologics

MidCap Financial

Debt Financing - Forge Biologics

State of Ohio

Grant - Forge Biologics

RA Capital Management

Series B - Forge Biologics

Perceptive Advisors

Series A - Forge Biologics

Grove City

Ohio

United States

North America

Forge Biologics

Charles River to lay off 3% of staffers as it streamlines spending

Australian RNA manufacturer launches; Forge Biologics’ CEO steps down

Ajinomoto will lay off 71 staffers in CA to streamline CDMO business following $620M Forge Biologics buy

Erandi De Silva, PhD on LinkedIn: Since Forge Biologics was acquired, I've spent the past few months… | 107 comments

A second co-founder has left Forge Biologics following its more than $600M acquisition

Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th ...

Forge Biologics on LinkedIn: Join us for a reception during the American Society of Gene & Cell Therapy…

[Video] John Maslowski on LinkedIn: #asgct2024 #aav #cdmo #genetherapy

Forge Biologics' Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK's Innovation ...

Canada

Philippines

Asia

Spain

Europe

India

Forge Biologics is a gene therapy development engine that provides end-to-end manufacturing services to accelerate gene therapy programs from preclinical stage through clinical and commercial manufacturing. The company is focused on developing innovative gene therapies to help patients suffering from devastating rare diseases.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 1:02 PM	18ce1570
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:02 PM	744dcc5a
company summary	general
signals	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	66d90951
crunchbase profile	general	Oct 31, 2024 10:50 AM	6d7114de
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	1b6a25e7
peers	general
news basic	general	Mar 8, 2024 1:02 PM	08bbcfa0
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

FORG

COM:FORGEBIOLOGICS

Forge Biologics